Analyse Delcath Systems, Inc. (DCTH) — Kairos Score 75/100

À propos de Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Informations clés

🕴️ Activité des initiés (90 jours)

2 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Delcath Systems, Inc..

🏦 Hedge Funds

7 fonds institutionnels déclarent une position sur DCTH dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur DCTH.

• Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
• 3 Emerging Biotech Stocks With Significant Upside Potential

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.